Skip to main content
Registrieren
Springer Medizin Österreich
SUCHE
MENÜ 1 2 3 4
nach oben

Tipp

Weitere Artikel dieser Ausgabe durch Wischen aufrufen

Erschienen in: memo - Magazine of European Medical Oncology 1/2018

23.02.2018 | Onkologie | editorial

Uro-oncology 2018: new horizons, new treatment options, improved patient outcomes

verfasst von: MD Ursula M. Vogl

Erschienen in: memo - Magazine of European Medical Oncology | Ausgabe 1/2018

Einloggen, um Zugang zu erhalten
share
TEILEN

Excerpt

The year 2018 is an exciting time to work as a uro-oncologist. Therapies have developed rapidly in the last year. …
Vorheriger Artikel Revival of anti-angiogenic therapies in cancer
Nächster Artikel In need of special care: adolescent and young adult patients with cancer
Literatur
1.
Vogl UM, Zehetgruber H, Dominkus M, Hejna M, Zielinski CC, Haitel A, et al. Prognostic factors in metastatic renal cell carcinoma: metastasectomy as independent prognostic variable. Br J Cancer. 2006;95(6):691–8. CrossRefPubMedPubMedCentral
2.
Zaid HB, Parker WP, Safdar NS, Gershman B, Erwin PJ, Murad MH, et al. Outcomes following complete surgical metastasectomy for patients with metastatic renal cell carcinoma: a systematic review and meta-analysis. J Urol. 2017;197(1):44–9. CrossRefPubMed
3.
Cornford P, Bellmunt J, Bolla M, Briers E, De SM, Gross T, et al. EAU-ESTRO-SIOG guidelines on prostate cancer. Part II: treatment of relapsing, metastatic, and castration-resistant prostate cancer. Eur Urol. 2017;71(4):630–42. CrossRefPubMed
4.
Gillessen S, Attard G, Beer TM, Beltran H, Bossi A, Bristow R, et al. Management of patients with advanced prostate cancer: the report of the advanced prostate cancer consensus conference APCCC 2017. Eur Urol. 2018;73(2):178–211. CrossRefPubMed
5.
Mottet N, Bellmunt J, Bolla M, Briers E, Cumberbatch MG, De SM, et al. EAU-ESTRO-SIOG guidelines on prostate cancer. Part 1: screening, diagnosis, and local treatment with curative intent. Eur Urol. 2017;71(4):618–29. CrossRefPubMed
6.
7.
Gravis G, Boher JM, Joly F, Soulie M, Albiges L, Priou F, et al. Androgen Deprivation Therapy (ADT) plus docetaxel versus ADT alone in metastatic non castrate prostate cancer: impact of metastatic burden and long-term survival analysis of the randomized phase 3 GETUG-AFU15 trial. Eur Urol. 2016;70(2):256–62. CrossRefPubMed
8.
James ND, Sydes MR, Clarke NW, Mason MD, Dearnaley DP, Spears MR, et al. Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial. Lancet. 2016;387(10024):1163–77. CrossRefPubMedPubMedCentral
9.
Sweeney CJ, Chen YH, Carducci M, Liu G, Jarrard DF, Eisenberger M, et al. Chemohormonal therapy in metastatic hormone-sensitive prostate cancer. N Engl J Med. 2015;373(8):737–46. CrossRefPubMedPubMedCentral
10.
Fizazi K, Tran N, Fein L, Matsubara N, Rodriguez-Antolin A, Alekseev BY, et al. Abiraterone plus prednisone in metastatic, castration-sensitive prostate cancer. N Engl J Med. 2017;377(4):352–60. CrossRefPubMed
11.
Sweeney C, Davis I et al. Enzalutamide in First Line Androgen Deprivation Therapy for Metastatic Prostate Cancer (ENZAMET), NCT02446405. 2018.
12.
Escudier B, Tannir N, McDermott D. CheckMate 214: efficacy and safety of nivolumab + ipilimumab (N+I) v sunitinib (S) for treatment-naive advanced or metatstatic renal cell carcinoma (mRCC), including IMDC risk and PDL-1 expression subgroups. 2018.
13.
Bellmunt J, Bajorin DF. Pembrolizumab for advanced urothelial carcinoma. N Engl J Med. 2017;376(23):2304–8. PubMed
14.
Bellmunt J, de WR, Vaughn DJ, Fradet Y, Lee JL, Fong L, et al. Pembrolizumab as second-line therapy for advanced urothelial carcinoma. N Engl J Med. 2017;376(11):1015–26. CrossRefPubMedPubMedCentral
15.
Powles T, Duran I, van der Heijden MS, Loriot Y, Vogelzang NJ, De GU, et al. Atezolizumab versus chemotherapy in patients with platinum-treated locally advanced or metastatic urothelial carcinoma (IMvigor211): a multicentre, open-label, phase 3 randomised controlled trial. Lancet. 2017; https://​doi.​org/​10.​1016/​S0140-6736(17)33297-X.
16.
Rosenberg JE, Hoffman-Censits J, Powles T, van der Heijden MS, Balar AV, Necchi A, et al. Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial. Lancet. 2016;387(10031):1909–20. CrossRefPubMedPubMedCentral
17.
Sharma P, Retz M, Siefker-Radtke A, Baron A, Necchi A, Bedke J, et al. Nivolumab in metastatic urothelial carcinoma after platinum therapy (CheckMate 275): a multicentre, single-arm, phase 2 trial. Lancet Oncol. 2017;18(3):312–22. CrossRefPubMed
18.
Petrylak DP, de Wit R, Chi KN, Drakaki A, Sternberg CN, Nishiyama H, et al. Ramucirumab plus docetaxel versus placebo plus docetaxel in patients with locally advanced or metastatic urothelial carcinoma after platinum-based therapy (RANGE): a randomised, double-blind, phase 3 trial. Lancet. 2017;390(10109):2266–77. CrossRefPubMed
19.
Bellmunt J, Theodore C, Demkov T, Komyakov B, Sengelov L, Daugaard G, et al. Phase III trial of vinflunine plus best supportive care compared with best supportive care alone after a platinum-containing regimen in patients with advanced transitional cell carcinoma of the urothelial tract. J Clin Oncol. 2009;27(27):4454–61. CrossRefPubMed
20.
Alexandrov LB, Nik-Zainal S, Wedge DC, Aparicio SA, Behjati S, Biankin AV, et al. Signatures of mutational processes in human cancer. Nature. 2013;500(7463):415–21. CrossRefPubMedPubMedCentral
Metadaten
Titel
Uro-oncology 2018: new horizons, new treatment options, improved patient outcomes
verfasst von
MD Ursula M. Vogl
Publikationsdatum
23.02.2018
Verlag
Springer Vienna
Schlagwort
Onkologie
Erschienen in
memo - Magazine of European Medical Oncology / Ausgabe 1/2018
Print ISSN: 1865-5041
Elektronische ISSN: 1865-5076
DOI
https://doi.org/10.1007/s12254-018-0393-1

Weitere Artikel der Ausgabe 1/2018

memo - Magazine of European Medical Oncology 1/2018 Zur Ausgabe

comment

ESMO 2017—my personal highlights

review

Novel guidelines on surveillance for breast cancer, cardiomyopathy, male gonadotoxicity, and premature ovarian insufficiency from the PanCare and International Guideline Harmonization Group on long-term follow-up after cancer in childhood

short review

Short overview on the current standard of treatment in newly diagnosed multiple myeloma

short review

Practice-changing developments in early use of chemohormonal therapy in metastatic prostate cancer

review

My burning issues in the neoadjuvant treatment for breast cancer

short review

Anti-angiogenic therapies in brain metastases